10x Genomics, Inc. (TXG) stock plunged 9.83% in the pre-market session on Thursday after the company reported disappointing fourth-quarter results and issued weak guidance for 2025, further exacerbated by concerns over potential cuts to National Institutes of Health (NIH) funding.
The biotech company, known for its gene sequencing and analysis products, faced a challenging year in 2024, with total revenue for the year decreasing by 1% compared to 2023. The company cited a difficult macroeconomic environment as a key factor impacting its performance. Additionally, 10x Genomics' revenue is heavily reliant on NIH funding, which accounts for 20-25% of its total revenue. The recent announcement of caps on indirect cost reimbursements by the NIH has raised concerns about the potential impact on the company's future revenue streams.
Moreover, 10x Genomics provided lackluster guidance for 2025, projecting revenue growth of only 0-3% compared to 2024. This disappointing outlook, coupled with lingering uncertainties surrounding NIH funding and the company's ongoing reorganization efforts, has led to a significant sell-off in the stock during the pre-market session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。